ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACAD
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.60103 billion
  • Outstanding Shares: 122,400,000
Average Prices:
  • 50 Day Moving Avg: $33.31
  • 200 Day Moving Avg: $31.51
  • 52 Week Range: $20.68 - $40.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.78
  • P/E Growth: -0.51
Sales & Book Value:
  • Annual Revenue: $62.99 million
  • Price / Sales: 73.04
  • Book Value: $3.39 per share
  • Price / Book: 11.09
  • EBIDTA: ($305,320,000.00)
  • Net Margins: -485.14%
  • Return on Equity: -62.08%
  • Return on Assets: -57.18%
  • Current Ratio: 10.85%
  • Quick Ratio: 10.70%
  • Average Volume: 1.46 million shs.
  • Beta: 3.9
  • Short Ratio: 13.54

Frequently Asked Questions for ACADIA Pharmaceuticals (NASDAQ:ACAD)

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.17. The company earned $30.50 million during the quarter, compared to the consensus estimate of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. ACADIA Pharmaceuticals's revenue was up 30400.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.63) earnings per share. View ACADIA Pharmaceuticals' Earnings History.

When will ACADIA Pharmaceuticals make its next earnings announcement?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for ACADIA Pharmaceuticals.

Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?

12 brokerages have issued 1-year price objectives for ACADIA Pharmaceuticals' stock. Their forecasts range from $25.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $44.17 in the next twelve months. View Analyst Ratings for ACADIA Pharmaceuticals.

What are analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (8/11/2017)
  • 2. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:

  • Stephen R. Biggar M.D. Ph.D., Chairman of the Board
  • Stephen R. Davis, President, Chief Executive Officer, Director
  • Todd S. Young, Executive Vice President, Chief Financial Officer
  • Glenn F. Baity, Executive Vice President, General Counsel, Secretary
  • Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development
  • Michael J. Yang, Executive Vice President, Chief Commercial Officer
  • Edmund P. Harrigan M.D., Director
  • Julian C. Baker, Independent Director
  • Laura A. Brege, Independent Director
  • James M. Daly, Independent Director

Who owns ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (6.23%), BlackRock Inc. (4.58%), State Street Corp (3.06%), Janus Henderson Group PLC (2.99%) and Franklin Resources Inc. (2.93%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including AXA, Franklin Resources Inc., Dai Ichi Life Insurance Company Ltd, Alliancebernstein L.P., TD Asset Management Inc., Parametric Portfolio Associates LLC, Raymond James Financial Services Advisors Inc. and California State Teachers Retirement System. Company insiders that have sold ACADIA Pharmaceuticals stock in the last year include Glenn Baity and Terrence O Moore. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Goldman Sachs Group Inc., First Trust Advisors LP, State Street Corp, Elliott Management Corp, Sectoral Asset Management Inc, NF Trinity Capital Hong Kong Ltd and Pictet Asset Management Ltd.. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Edmund Harrigan and LP 14159. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy ACADIA Pharmaceuticals stock?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $37.59.

MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  443 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  623
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $44.17 (17.50% upside)

Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Needham & Company LLCReiterated RatingBuy$49.00LowView Rating Details
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$54.00HighView Rating Details
8/10/2017Cowen and CompanyReiterated RatingOutperform$42.00 -> $46.00HighView Rating Details
8/9/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00LowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingBuy$47.00LowView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$49.00 -> $48.00N/AView Rating Details
1/11/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
12/28/2016Leerink SwannReiterated RatingMarket Perform$29.00N/AView Rating Details
11/11/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$28.00N/AView Rating Details
11/8/2016Bank of America CorporationUpgradeNeutral -> Buy$35.00N/AView Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/AView Rating Details
8/10/2016JMP SecuritiesReiterated RatingBuy$45.00N/AView Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00N/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings History by Quarter for ACADIA Pharmaceuticals (NASDAQ ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.63)N/AView Earnings Details
8/8/2017Q2 2017($0.72)($0.55)$20.02 million$30.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.73)($0.72)$15.17 million$15.30 millionViewListenView Earnings Details
2/28/2017Q416($0.65)($0.65)$9.05 million$12.00 millionViewListenView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.25)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)$0.02 millionViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)$0.10 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)$0.50 million$0.03 millionViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)
2017 EPS Consensus Estimate: ($2.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.75)($0.53)($0.64)
Q2 20172($0.71)($0.48)($0.60)
Q3 20172($0.64)($0.44)($0.54)
Q4 20172($0.62)($0.39)($0.51)
(Data provided by Zacks Investment Research)


Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 97.10%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/30/2017Glenn BaityEVPSell26,507$34.87$924,299.09View SEC Filing  
8/9/2017Glenn BaityEVPSell14,322$34.88$499,551.36View SEC Filing  
7/20/2017Glenn BaityEVPSell38,097$30.00$1,142,910.00View SEC Filing  
6/22/2017Glenn BaityEVPSell1,903$30.00$57,090.00View SEC Filing  
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.00View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.00View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateHeadline logoACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of "Buy" by Analysts - September 24 at 2:48 PM logoCommit To Buy Acadia Pharmaceuticals At $25, Earn 8.2% Using Options - September 23 at 9:37 AM logoHead-To-Head Contrast: INC Research Holdings (INCR) & ACADIA Pharmaceuticals (ACAD) - September 21 at 12:44 AM logoTechnical Reports on Biotech Equities -- Vanda Pharma, ACADIA Pharma, Achillion Pharma, and Agios Pharma - PR Newswire (press release) - September 20 at 3:17 PM logoAcadia: Where's The Upside From Current Levels? - Seeking Alpha - September 20 at 3:17 PM logoSupernus Drops SPN-810's Lower Dose Test in Phase III Trials - September 19 at 8:24 PM logoSupernus Drops SPN-810's Lower Dose Test in Phase III Trials - September 19 at 8:23 PM logoACADIA Pharmaceuticals to Present at the Ladenburg Thalmann ... - Business Wire (press release) - September 19 at 3:23 PM logoACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017 - September 19 at 3:23 PM logoACADIA Pharmaceuticals Inc. (ACAD) Expected to Post Quarterly Sales of $31.52 Million - September 18 at 4:48 AM logoACADIA Pharmaceuticals Inc. (ACAD) Receives "Buy" Rating from Needham & Company LLC - September 17 at 8:48 AM logoZacks: Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) to Post -$0.63 EPS - September 16 at 6:28 PM logoHead-To-Head Review: ACADIA Pharmaceuticals (ACAD) & PAREXEL International Corporation (PRXL) - September 16 at 4:10 PM logoAlexion (ALXN) Reports Interim Results for Soliris Study - September 14 at 3:20 PM logoAcadia Stock Recovers From Recent Slump, Posts Strong Quarterly Numbers - September 12 at 3:20 PM logoMarinus Stock Surges on Successful Phase II Epilepsy Study - September 12 at 3:20 PM logoToday's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology - September 11 at 3:58 PM logoNuplazid Sees Increasing Physician Intent to Prescribe in 2017 - September 8 at 8:38 PM logoNuplazid for Long-Term Care: Revenue Driver for Acadia? - September 8 at 8:38 PM logoNuplazid Expected to Become a Leading Central Nervous System Drug - September 8 at 3:35 PM logoAcadia Could Report Robust Revenue Growth in 2017 - September 7 at 3:18 PM logoMerck (MRK) Opts for Buying German Immuno-Oncology Biotech - September 7 at 3:18 PM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : September 7, 2017 - September 7 at 3:18 PM logoBioMarin Presents Interim Data on BMN 250 from Phase I/II - September 7 at 3:18 PM logoACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 - September 5 at 3:31 PM logoACADIA Pharmaceuticals Inc. (ACAD) Lifted to Hold at ValuEngine - September 4 at 12:00 AM logoInsider Selling: ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells 26,507 Shares of Stock - September 1 at 7:20 PM logoStocks To Watch: Acadia Pharmaceuticals Sees RS Rating Jump To 83 - August 30 at 3:23 PM logoFDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down - August 30 at 3:23 PM logoACADIA Stock Recovers From Recent Slump, Posts Strong Quarterly Numbers - Seeking Alpha - August 29 at 3:43 PM logoACADIA Stock Recovers From Recent Slump, Posts Strong Quarterly Numbers - Seeking Alpha - August 29 at 3:43 PM logoAdamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments - Benzinga - August 25 at 4:58 PM logoKite Pharma at New 52-Week High: What's Driving the Stock? - August 24 at 3:21 PM logoUltragenyx (RARE) Posts Disappointing Phase III Ace-ER Data - August 23 at 8:23 PM logoJazz Pharmaceuticals Arm Announces $500M Senior Notes Offer - August 18 at 3:21 PM logoAcadia Pharmaceuticals Has Huge Opportunities Ahead - August 15 at 8:46 PM logoBig-Name US Hedge Funds Shed Healthcare Stocks During the Rally in Second Quarter - New York Times - August 14 at 3:29 PM logo$29.03 Million in Sales Expected for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) This Quarter - August 12 at 5:38 AM logoACADIA Pharmaceuticals Inc. (ACAD) Upgraded to Buy at Zacks Investment Research - August 11 at 9:46 PM logoACADIA Pharmaceuticals Inc. (ACAD) EVP Sells $499,551.36 in Stock - August 11 at 7:52 PM logoQ3 2017 EPS Estimates for ACADIA Pharmaceuticals Inc. Raised by Analyst (ACAD) - August 11 at 10:14 AM logoSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. - August 11 at 2:57 AM logoACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Post Earnings of -$0.69 Per Share - August 10 at 8:22 PM logoACADIA Reports Strong Earnings Resulting From Accounting Change - Seeking Alpha - August 10 at 4:52 PM logoACADIA Pharmaceuticals Inc. (ACAD) PT Set at $54.00 by Piper Jaffray Companies - August 10 at 9:08 AM logoAcadia Shares Up Big On Strong Sales, Increased Confidence - Benzinga - August 10 at 1:35 AM logo'Longing' for Acadia Pharmaceuticals? Here's How to Play It - August 9 at 8:34 PM logoHere's Why Acadia Pharmaceuticals Inc. Is Soaring Today - Motley Fool - August 9 at 3:33 PM logoEdited Transcript of ACAD earnings conference call or presentation 8-Aug-17 9:00pm GMT - August 9 at 3:33 PM logoBiotech Acadia Sends a Loud Message to the Market - August 9 at 3:33 PM



ACADIA Pharmaceuticals (ACAD) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by Staff